Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034   30/04/2025
2,205 USD (-1,12%)
(-1,12%)   30/04/2025

28 april 2025 · RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 · Persbericht

17 april 2025 · RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency · Persbericht

16 april 2025 · RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption · Persbericht

10 april 2025 · RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights · Persbericht

18 maart 2025 · RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation · Persbericht

12 maart 2025 · RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results · Persbericht

9 september 2024 · RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines · Persbericht

5 september 2024 · RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

3 september 2024 · New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality · Persbericht

29 augustus 2024 · RedHill Biopharma Announces First Half 2024 Business Highlights · Persbericht

26 augustus 2024 · RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma · Persbericht

21 augustus 2024 · Talicia® Launched in the United Arab Emirates · Persbericht

19 augustus 2024 · RedHill Announces Positive Obesity and Diabetes Results with Opaganib · Persbericht

16 augustus 2024 · RedHill Biopharma Announces Plan to Implement ADS Ratio Change · Persbericht

1 augustus 2024 · Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease · Persbericht

22 juli 2024 · RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien · Persbericht

9 juli 2024 · RedHill Biopharma Terminates License Agreement for Aemcolo® · Persbericht

6 mei 2024 · RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 · Persbericht

24 april 2024 · RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study · Persbericht

8 april 2024 · RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights · Persbericht

Mijn selecties